Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Catalyst Biosciences Inc    CBIO

CATALYST BIOSCIENCES INC

(CBIO)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/16/2019 | 08:01am EDT

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development (HDD) Summit being held from August 20-22, 2019 in Boston.  

Dr. Howard Levy, chief medical officer of Catalyst, will discuss previously presented preclinical and clinical data of the Company’s two subcutaneous factors for prophylaxis, Factor VIIa, marzeptacog alfa (activated) (MarzAA) and Factor IX, dalcinonacog alfa (DalcA), comparing and contrasting their clinical use due to differences in their pharmacokinetic properties.  Dr. Grant Blouse, vice president, translational research at Catalyst, will lead a workshop on understanding the immunogenicity of coagulation factor replacement products.

Oral presentation details
 
   Presentation Title: A Tale of Two Subcutaneous Coagulation Factors
   Presenter: Howard Levy, M.B.B.Ch., Ph.D., M.M.M.
   Session: Advancing Novel Prophylaxis that Improves Quality of Life for Patients
   Date/Time: Wednesday, Aug. 21 from 12:30 – 1 p.m. EDT
      
Workshop details
      
   Presentation Title: Understanding Immunogenicity in Next Generation Factor Replacement Prophylaxis
   Presenter: Grant Blouse, Ph.D.
   Session: Workshop A
   Date/Time: Tuesday, Aug. 20 from 9:00 a.m. – 12:00 p.m. EDT

 


A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website once the presentations conclude.

About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel treatments  for hemophilia and other rare bleeding disorders using its potent, subcutaneous (SQ) coagulation factors that promote blood clotting. The Company’s engineered coagulation factors are designed to overcome the significant limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes using SQ dosing. For more information, please visit www.catalystbiosciences.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential uses and benefits of MarzAA and DalcA to treat patients with hemophilia, clinical trial results and immunogenicity risks. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA or DalcA, including the generation of antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s annual report filed with the Securities and Exchange Commission on March 8, 2019, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
1.650.871.0761
investors@catbio.com

Media:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
1.646.751.4361
jo@lifescipublicrelations.com

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CATALYST BIOSCIENCES INC
08/19CATALYST BIOSCIENCES : to Present at the 2019 Hemophilia Drug Development Summit
AQ
08/16Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summi..
GL
08/09CATALYST BIOSCIENCES : to Host Key Opinion Leader Meeting on Next-Generation Sub..
AQ
08/08CATALYST BIOSCIENCES : to Host Key Opinion Leader Meeting on Next-Generation Sub..
AQ
08/01CATALYST BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
AQ
08/01CATALYST BIOSCIENCES, INC. : Results of Operations and Financial Condition, Fina..
AQ
08/01CATALYST BIOSCIENCES : Reports Second Quarter 2019 Operating & Financial Results..
AQ
07/09CATALYST BIOSCIENCES : Meets the Primary Endpoint of Reduction in Annualized Ble..
AQ
07/08Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bl..
GL
07/01Catalyst Biosciences Announces Oral and Poster Presentations at the Internati..
GL
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -59,2 M
Net income 2019 -57,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -1,51x
P/E ratio 2020 -1,60x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 87,4 M
Chart CATALYST BIOSCIENCES INC
Duration : Period :
Catalyst Biosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALYST BIOSCIENCES INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 24,00  $
Last Close Price 7,27  $
Spread / Highest target 230%
Spread / Average Target 230%
Spread / Lowest Target 230%
EPS Revisions
Managers
NameTitle
Nassim Usman President, Chief Executive Officer & Director
Augustine J. Lawlor Chairman
C. Fletcher Payne CFO & Principal Accounting Officer
Howard Levy Chief Medical Officer
Errol B. de Souza Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST BIOSCIENCES INC-7.86%87
CSL LIMITED26.62%72 390
BIOGEN INC.-23.14%43 009
ALEXION PHARMACEUTICALS17.95%25 750
GRIFOLS27.07%19 474
SAMSUNG BIOLOGICS CO LTD--.--%15 595